6527.Two
6527.TWO operates in the healthcare services and equipment industry, primarily generating revenue through the provision of medical equipment, supplies, and distribution services.
Business. 6527.TWO operates in the healthcare services and equipment industry, primarily generating revenue through the provision of medical equipment, supplies, and distribution services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
6527.TWO operates in the healthcare services and equipment industry, primarily generating revenue through the provision of medical equipment, supplies, and distribution services.
The company maintains a strong liquidity position, with a current ratio of 2.45 and cash and equivalents amounting to TWD 132,018,000. Its debt-to-equity ratio is 0.01, indicating a conservative capital structure with minimal reliance on long-term debt. The price-to-book ratio of 1.74 suggests that the company is trading at a premium to its book value, which may reflect market confidence in its asset base and earnings potential.
Profitability metrics show that the company is performing well relative to industry norms. It reports a return on equity (ROE) of 14.29% and a return on assets (ROA) of 11.35%, both of which are strong indicators of efficient capital utilization and asset management. The net income of TWD 146,980,000 and operating income of TWD 180,945,000 further support the company's profitability. Gross profit of TWD 331,879,000 indicates a healthy margin, although the exact comparison to industry medians is not provided in the data.
The company's revenue is concentrated in the medical equipment, supplies, and distribution segment, as disclosed in its financials. There is no indication of geographic diversification in the provided data, suggesting that the company's operations are likely centered in a specific region. This concentration may expose the company to regional economic or regulatory risks.
Looking ahead, the company is expected to maintain a stable growth trajectory. While specific numeric deltas for the current and next fiscal years are not provided, the company's strong operating cash flow of TWD 139,131,000 and revenue of TWD 949,049,000 suggest a solid foundation for future growth. The company's capital expenditure of TWD -185,187,000 indicates ongoing investment in infrastructure and operations, which could support long-term expansion.
The risk assessment indicates a low level of liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and strong cash reserves further support this assessment. There is no evidence of dilution potential in the basic shares outstanding, as the number of basic and diluted shares is the same. The company has not made any adjustments to its valuations that would suggest a need for dilution or restructuring.
Recent events, including filings and transcripts, do not indicate any material changes or risks to the company's operations. The absence of filing-based liquidity or dilution flags suggests that the company is currently in a stable financial position. However, ongoing monitoring of capital expenditures and operating cash flow will be important to assess the sustainability of its growth and profitability.
- The company has a strong liquidity position with a current ratio of 2.45 and minimal long-term debt.
- It demonstrates high profitability with a return on equity of 14.29% and a return on assets of 11.35%.
- The company's revenue is concentrated in the medical equipment, supplies, and distribution segment, with no geographic diversification disclosed.
- The company is expected to maintain a stable growth trajectory, supported by strong operating cash flow and revenue.
- Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 6527.TWO Market data — financials · 2026-05-27
Ownership & reference
Leadership
- William WangChairman of the Board, Chief Executive Officer